Abstract
Introduction
The cardiac effects of hypertension are evident both in structure, where left ventricular hypertrophy (LVH) is a powerful independent marker of mortality, 1, 2 and in function, where systolic and predominately diastolic abnormalities are evident. 3 LVH is also associated with impaired diastolic function, increased risk of ventricular arrhythmias, myocardial infarction and sudden death 4, 5 and has an additive effect on vascular risk in the presence of hypertension. 6 Indeed, as regression of LVH can improve outcome, 7 LVH and its response to treatment has become an important surrogate measurement in hypertension.
The same can also be said of arterial stiffness, which has been shown to be an independent coronary risk factor. 8 Along with ageing, diabetes mellitus and hypercholesterolaemia, hypertension is associated with increased arterial stiffness at an early stage. 9 Stiffening of the arterial tree may accelerate atherosclerosis directly, possibly by decreasing shear stress, 9 but also by raising central systolic pressure, which in turn increases the risk of cerebrovascular disease and accelerates arteriosclerosis, hereby further increasing stiffness -initiating a vicious circle. Owing to variable amplification of systolic blood pressure (BP), from the aorta to the peripheral arteries, occurring due to a combination of wave reflection and changes in arterial compliance, peripheral BP does not always accurately reflect central BP. 10 Indeed, increases in left ventricular mass index (LVMI) 11 relate better to the central, than to the peripheral arterial waveform. Essential hypertension is also known to be associated with eutrophic remodelling of resistance vessels, which is associated with an increase in wall thickness to lumen diameter ratio, 12 not always involving vascular growth, but instead rearrangement of the same amount of material. 13 Angiotensin II is known to cause myocyte hypertrophy and myocardial fibrosis in vitro, 14 both integral features of hypertensive heart disease. To date, non-specific blockade of the renin-angiotensin system (RAS), via angiotensinconverting enzyme (ACE) inhibition, has been shown to be the most effective treatment available to reduce LVH. 15 We hypothesised that specific blockade of the vascular effects of angiotensin II at the AT 1 -receptor, using candesartan, would lead to a significant reduction in left ventricular mass and reversal of the adaptive vascular changes seen in hypertension.
Methods
This study was designed as an open, non-comparative study of the effect of candesartan on left ventricular mass and cardiovascular structure and function and was conducted at four centres (see Acknowledgements) in the United Kingdom. The study protocol was approved by an independent ethics committee for each centre before enrolment in the study. The study was performed in accordance with the Declaration of Helsinki. Fully informed written consent was obtained from all study subjects.
Subjects

Inclusion criteria
Subjects aged >20 years with hypertension, (defined as a mean sitting diastolic blood pressure [DBP] of 95-115 mmHg), either untreated or treated with a maximum of two antihypertensive medications withdrawn four weeks before the study, were eligible for inclusion. Subjects were required to have a mean seated DBP between >95 and 115 mmHg after four weeks' placebo run-in, and co-existing LVH, according to an M-mode transthoracic echocardiography (TTE) recording taken at entry to the placebo run-in period and read locally at each respective study site (LVH defined as left ventricular mass index >125 g/m 2 for men; >110 g/m 2 for women).
16
Exclusion criteria Exclusion criteria included pregnancy or lactation, secondary or malignant hypertension, treatment with systemic corticosteroids, non-steroidal anti-inflammatory drugs,ACE inhibitors (ACE-I) or angiotensin AT 1 -receptor blockers (ARBs) in the previous six months, or a history of myocardial infarct (MI). Operative coronary artery intervention or cerebrovascular event in the previous six months, angina pectoris or cardiac failure requiring treatment with calcium channel blockers, beta blockers or potassium channel openers and clinically significant abnormalities in renal or hepatic function were additional exclusion criteria. Patients with echocardiographic evidence of haemodynamically significant valvular disease or with LV ejection fraction <40%, and those with atrial fibrillation or significant (> grade II) atrioventricular block were also excluded. At the first visit, before the placebo run-in period, sitting systolic blood pressure (SBP), DBP and heart rate (HR) were measured in both arms and the arm with the higher mean DBP was used for subsequent readings.At each subsequent visit, sitting BP and HR were recorded three times and the mean recorded. Cardiac structure and function was assessed by transthoracic echocardiography (TTE), with an M-mode screening study performed before the placebo run-in period to identify LVH, and 2D and doppler TTE studies performed after the placebo run-in period (baseline, week 0) and after 24 weeks of active treatment. Patients had baseline measurements taken of TTE, ambulatory BP monitoring (ABPM), minimum forearm vascular resistance (MFVR) and pulse wave analysis (PWA). Subjects continued to attend at monthly intervals for BP readings until week 24, at which time measurements of TTE,ABPM, MFVR and PWA were repeated and the study concluded. Subjects were instructed to return all unused study medication at the end of each treatment period to assess compliance. 24-hour ABPM, PWA and MFVR measurements were done only on patients at centres 1 and 2, thus the number of subjects giving results in these parameters is lower.
Study design
Study assessments
Sitting systolic blood pressure and diastolic blood pressure A semi-automated oscillometric BP device (OMRON HEM-705CP) 17 recorded seated BP and heart rate at each visit in the morning prior to drug administration, after the subject had rested for at least 5 minutes, 24±2 hours after the previous dose of candesartan.
24-hour ambulatory blood pressure monitoring
Subjects were fitted with a BP monitor (Space-Lab model 90207), instructed to pursue normal physical activities, but to avoid strenuous exercise and remain still during cuff inflation. The cuff was placed on the non-dominant arm and measurements taken at 30-minute intervals. Caffeine intake was restricted to one cup of tea/coffee every 4 hours and event diaries were recorded.ABPM was performed for 26 hours with physiologicallyimpossible values and the first 2 hours of recordings discarded. Recordings were only included if <20% of the readings were deleted.
Transthoracic echocardiography LVMI was calculated by 2D TTE, 18 as previously described, and subsequently indexed for body surface area (LVMI = LVM / BSA-g/m 2 ). Systolic function was assessed by ejection fraction, measured by 2D TTE. Diastolic function was assessed by doppler TTE, using the parameters of: diastolic time (ms); peak velocity of early, rapid filling (cm/s) (E); peak velocity during atrial contraction (cm/s) (A) and E:A ratio.
Two independent assessors at a core laboratory analysed the 2D TTE recordings off-line, with the average value for each variable subsequently used in the analyses. If the difference between the assessors was >10-20% (the percentage level depending on the variable), a consensus was reached by consultation.The assessors were blinded to whether recordings were from the baseline or the end of the study. Pulse wave analysis Augmentation index was determined by PWA, 19 a reproducible 20 method of assessing arterial stiffness that provides a non-invasive estimate of large vessel compliance, using the SphygmoCor apparatus (SCOR; PWV Medical, Sydney, Australia). A high fidelity micromanometer (SPC-301, Millar Instruments, Texas, USA) was used to flatten the radial artery in the non-dominant hand at the wrist, using gentle pressure. Data were collected directly into a portable computer. After 20 sequential waveforms had been acquired, the integral software was used to generate an averaged peripheral and corresponding central waveform. From this, the augmentation index (AIx) (defined as the difference between the second (P 2 ) and first (P 1 ) peaks of the central arterial waveform, expressed as a percentage of the pulse pressure) and central SBP and DBP from aortic waveform (mmHg) were determined.
Minimum forearm vascular resistance
Forearm venous occlusion plethysmography was used to calculate MFVR, which provides an estimate of resistance vessel structure, 21 and which correlates highly with media to lumen ratio. 22 Blood flow was measured in the left forearm by venous occlusion plethysmography, by use of a mercury-in-silastic strain gauge, as previously described. 23 Recordings of forearm blood flow (FBF) were made, after a 20 minute period of rest, at 10 minute intervals over 30 minutes. 23 Forearm vascular resistance was calculated from measurements of FBF and mean arterial pressure (as the ratio between mean arterial pressure and FBF, expressed as arbitrary units). Limb ischaemia was then achieved by the application of a cuff inflated on the proximal forearm to suprasystolic pressure for 13 minutes and FBF measured as the peak flow in the minute following deflation of the cuff. 21 Voltage output from a Vasculab SPG 16 straingauge plethysmograph (Medasonics, Inc) was transferred to a Macintosh personal computer by a Maclab analogue digital converter and Chart software (AD Instruments). Calibration was achieved by use of the internal standard of the Vasculab plethysmography units.
Statistical analyses
The analysis of efficacy estimates the effect of treatment as the least squares mean of a one sample Analysis of Covariance (ANCOVA) of the change from baseline to the last visit, with the centre as a fixed factor and baseline levels as a covariate. The least squares mean was obtained as the value of a linear hypothesis vector, having as components the standard value of the intercept and the mean value of the co-variate using the statistical analysis package SAS.This estimate is given with 95% confidence limits, and p-value for the test of the hypothesis that the true value is zero. The confidence limits and p-values were calculated using the residual mean squares from the fitted ANCOVA. All results have been analysed and displayed using the intention to treat (ITT) data set.
Results
In total, 48 subjects from the United Kingdom were enrolled in the study at four centres. During the placebo run-in period, 13 subjects discontinued; the study; (11 did not fulfil the eligibility criteria and two were lost to follow-up). Thirty-five subjects were therefore eligible to enter the active treatment period; of these, three subjects were withdrawn owing to failure to achieve pre-defined BP targets. No discontinuation due to adverse events occurred.When the echocardiograms were PAPER Table 1 Effects on ambulatory blood pressure over the 24-hour dosing interval and in office blood pressure and heart rate 24 hours post-dose, after 24 weeks of treatment with candesartan cilexetil 16 mg (± hydrochlorothiazide 12.5 mg) once-daily. analysed by the independent assessors, nine further subjects were excluded (five for poor image quality, four due to missing values) from the 2D TTE analyses, leaving 23 subjects with complete data sets for analysis.
Baseline characteristics
The population included 35 subjects (24 male and 11 female), of whom 85% were Caucasian and 15% Afro-Caribbean.The mean age was 48 years (SD 13 years), with a mean weight and body mass index of 82 kg (SD 13 kg) and 28 kg/m (SD 4 kg/m ). The mean SBP was 169 mmHg (SD 19) and mean DBP was 104 mmHg (SD 10).
ABPM and sitting blood pressure
Sitting BP was significantly reduced with treatment, whereas heart rate did not change (Table 1) . Ambulatory BP was also significantly reduced with treatment, with 21 subjects (60%) requiring HCTZ add-on therapy.
LVMI and left ventricular function
Candesartan cilexetil, 16 mg o.d., ±HCTZ, for 24 weeks significantly reduced LVMI as assessed by 2D TTE (Figure 1 ), whereas ejection fraction did not change (Table 2) . However, diastolic time increased by 54 ms, peak velocity of rapid filling by 6.3 cm/s and E/A ratio by 0.08, giving a consistent improvement in diastolic function (see Table  2 ). Regression analysis found no clear relationship between the changes in LVMI and BP, although there was a weak, non-significant trend towards a greater reduction in LVMI in the patients who had the greatest falls in BP.
Arterial structure/compliance Augmentation index, central systolic and diastolic BP were reduced compared with baseline. Amplification of BP was reduced by treatment of BP with candesartan (baseline = 1.19, post treatment = 1.33, p<0.01). Forearm vascular resistance and MFVR were significantly reduced at rest and after limb ischaemia (Table 3) .
Adverse events (AE)
The only serious AE reported (leg fracture due to a fall) had no suspected relationship to the study drugs. The type and frequency of non-serious AE during the placebo run-in and active treatment periods were similar and no discontinuation due to AE occurred. No clinically significant changes in laboratory values of liver or renal function tests were observed.
Discussion
This is the first non-invasive, clinical study to assess the effect of AT 1 -receptor blockade on both arterial and cardiac structure and function in hypertensive patients. We demonstrated a small reduction in LVMI, as assessed by 2D TTE, following 24 weeks treatment with candesartan ± HCTZ, associated with a reduction in peripheral and central BP, improvement in cardiac diastolic function and reduction in both AIx and MFVR. It should be noted that the baseline LVMI values from the blinded assessment of 2D TTE were PAPER lower than the original LVMI entry criteria based on the local, study-site assessment of the screening M-mode TTE. The relatively low baseline LVMI may explain the relatively modest decrease in LVMI with treatment. As expected, sitting peripheral BP fell significantly. Although the study was not placebo-controlled, there was a four-week placebo run-in phase, designed to reduce any potential overestimate of the effect of candesartan on BP and to minimise the chance of any carry-over effect from previous antihypertensive therapy. Futhermore, treatment with an ACE-I or ARB in the previous six months was not allowed, in order to avoid any potential influence of such treatments on structural or functional cardiovascular parameters. Mean 24-hour ABPM, which has minimal, if any placebo effect, 24 also showed a marked reduction in BP, suggesting that candesartan administered once-daily reduces BP over a 24-hour period. The initial BP was relatively high, explaining why 21 subjects needed HCTZ add-on therapy to achieve target BP.
Of interest was the marked improvement seen in diastolic heart function. It has been well documented that diastolic dysfunction is an important sign of hypertensive heart disease and may increase the rate of progression of coronary artery disease. 3 Studies of unselected hypertensive populations have suggested incidences of diastolic dysfunction of up to 46%, a figure that is increased in the presence of LVH. 25 The co-existence of diastolic dysfunction and LVH leads to an increased total coronary artery flow demand and a decrease in the vasodilator capacity of coronary arterioles, which in turn may result in myocardial ischaemia. 26 Characteristic changes of diastolic dysfunction include reduction in diastolic filling, peak filling rate and average rate of early filling, which are pronounced in the presence of LVH. 3 Treatment with candesartan increased diastolic time with no significant change in HR, indicating a greater distensibility of the left ventricle, with diastole making up a greater proportion of the cardiac cycle. Significant improvements in the E:A ratio were seen, indicating a greater proportion of ventricular filling being due to early, passive (E), rather than atrial filling (A), also suggesting an increase in ventricular compliance. Although peak filling rate improves with reduction of left ventricular mass, 27 regardless of the antihypertensive agent used, overall improvement in diastolic function is more variable, with data suggesting that blockade of the RAS is the most effective way of improving diastolic dysfunction. 28 As decreases in systolic function tend to occur later in the disease process, 29 and the target population had largely normal systolic function at baseline, it is not surprising that no significant change in systolic function was seen. Sub-set analysis of the data did not show any significance for the factors determining the fall in either LVMI or improvement in diastolic function. In both areas there was a trend to greater reduction with a higher starting blood pressure. However, the relatively small number of subjects makes sub-set analysis difficult.
Candesartan also significantly reduced the augmentation index.As arterial stiffness is dependent on distending pressure, the change in AIx could have been due solely to a reduction of mean arterial pressure, or may have directly represented changes in vessel stiffness. Our results would suggest that this decrease in AIx is multi-factorial; the fall in BP due to candesartan will have reduced the hypertension-induced large artery distension, 10 thereby shifting its reliance from collagenous to more elastic elements, and thereby increasing large artery compliance. The normal amplification of SBP from central to peripheral arteries, which is reduced in hypertension, 30 representing a combination of changes in vessel compliance and structure, was partially reversed. This increase in the amplification ratio, which has been previously demonstrated with ARBs, 31 would suggest that treatment with candesartan may decrease large artery stiffness and that the decrease in AIx is not solely due to changes in wave reflection. MFVR after ischaemia, as measured by venous occlusion plethysmography, was also significantly reduced. As local accumulation of metabolites during ischaemia inhibit the muscular tone and nervous influences that normally contract vascular smooth muscle, this strongly supports an effect on vessel structure, i.e. regression of the arterial hypertrophy seen in resistance arteries. [32] [33] [34] This suggests a favourable effect of ARBs on arterial structure as well as cardiac structure. These observations are consistent with recent reports demonstrating that ARBs reverse human resistance vessel hypertrophy and improve the media: lumen ratio and that this effect is not solely dependent on BP reduction, in that it was not reproduced by beta blockade. 33 We conclude, therefore, that antihypertensive treatment with candesartan cilexetil, 16 mg (± hydrochlorothiazide 12.5 mg) once-daily for 24 weeks is associated with significant and favourable regression of structural and functional hypertensive changes, both in the heart and in the blood vessels. This treatment provides a marked reduction in BP and is well tolerated. Because of the study design, it is impossible to say whether these changes are solely BP-dependent, or whether they are, at least in part, driven by selective blockade of the AT 1 -receptor. Moreover, it is unknown whether improvements in these surrogate markers of cardiac structure and function will be paralleled by improved morbidity and mortality. In this regard, the results of ongoing, large-scale, prospective, randomised, clinical trials of ARBs in patients with diastolic heart failure are timely and important. 35 
